Orthogen, LLC

Orthogen, LLC Continues to Develop Exemplary Nanotechnologies for Bone Regeneration


Springfield, NJ -- (SBWIRE) -- 09/06/2017 -- Since their days as biomaterial specialists at New York University, the scientists of Orthogen, LLC have been exploring the frontiers of biomedical research. Originally a division of BioLok International, Orthogen went independent as a company in 2007, continuing to focus on dental and orthodontic applications. Alongside Dr. Sachin Mamidwar and their professional circle of medical consultants, they are continually researching and developing bone regeneration nanotechnologies.

By working closely with institutions like Rutgers University and New York University School of Dentistry, Orthogen harnesses over a decade of research in dental bone graft materials. Patented as NanoGen, this proprietary technology converts calcium sulfate powders into a denser and finer particle. Because of the microscopic structure of NanoGen, it can be used as bone material during more traditional dental graftings. As NanoGen naturally degrades over 12-16 weeks, it spurs the formation of calcium phosphate and bone regeneration. Within 3 to 4 months, grafting sites are filled in with regenerated vital bone.

In tandem with NanoGen, Orthogen's exploration of bone grafting expanded to Dentogen, and calcium sulfate. Although in usage for 115 years, calcium sulfate was misperceived to be a mere defect filler. In their research, Orthogen conclusively demonstrated that calcium sulfate was more than highly biodegradableā€”it was also shown to stimulate bone growth, and proved non-toxic. Once implanted, the graft would dissolve into its constituent parts: calcium and sulfate ions. By the wonder of biochemistry, calcium and phosphate ions then bond into calcium phosphate.

To learn more about their latest research and innovations in dental bone grafting, one can visit their website at http://www.orthogencorp.com/.

About Orthogen, LLC
Originally a division of BioLok International, which is now merged with BioHorizons, Orthogen, LLC was established in 2007 to develop and market next generation bone-grafting products for orthopedic and dental applications. Dr. Sachin Mamidwar serves as CEO of the company whereas Dr. Harold Alexander, previously Director of Orthopedic research at the Hospital for Joint Diseases, New York, serves as the Chairman of the Board. Orthogen offers various products including DentoGenĀ®, NanoGen, collagen membranes, related instruments and sutures for dental applications.

To inquire about the company's products and technologies, please call 877-336-8643.